Key Drivers
- Strong liquidity
- High operating costs
- Improving quarterly profit
AIAI Summary
AtriCure has shifted from a binary clinical gamble to a cash‑generating, product‑led med‑tech where the investment hinge is sustaining procedure‑driven revenue and consecutive FCF/margin improvement to justify a rich valuation, while late‑stage trial success is the primary upside catalyst and trial delays/failure or margin compression are the main downside risks.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High operating costs
- •Improving quarterly profit
ATRC combines high gross margins, strong cash/FCF and low leverage with improving quarterly profitability, but persistent operating losses, very high R&D/SG&A, large intangibles and a stretched EV/EBITDA pose material profitability and valuation risks.
Price Behavior
Key Price Behavior Insights:
- •Short-term weakness
- •Near-oversold RSI
- •Support holding
Stock slipped from a February peak into a short-term downtrend: last month SMA ~ $30.40 sits above the $29.18 close, RSI near 31 approaches oversold, with support $28.80–$29.20 and immediate resistance $31.00–$32.60 (mid‑30s–low‑$40s remain longer‑term resistance).
Shift from
Sentiment & News
Key News Insights:
- •Analyst consensus
- •Citigroup accumulation
- •Insider trimming
AtriCure saw stronger institutional and analyst interest (Citigroup buying, “Moderate Buy” consensus) and increased investor outreach while a modest insider sale slightly trimmed holdings.
Overall sentiment is mildly positive due to outside buying and analyst support, but the insider sale limits near‑term upside until clearer operational catalysts emerge
Similar Companies in Healthcare
Other companies in the same sector with AI ratings